×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Drug Discovery Services Market Analysis

ID: MRFR/Pharma/4414-CR
110 Pages
Rahul Gotadki
December 2022

Drug Discovery Services Market Research Report Information By Drug Type (Small Molecule Drug, Biologics), By Type (DMPK, Pharmaceutical Services, Others), By Therapeutic Area (Oncology, Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Drug Discovery Services Market Infographic
×
Drug Discovery Services Market Infographic Full View
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Drug Discovery Services Market Industry Landscape

 The market dynamics of the drug discovery services sector embody a complex interplay of factors that influence its growth, trends, and evolution. At its core, the drug discovery services market is driven by the increasing demand for innovative therapeutics, propelled by rising incidences of chronic diseases and the pursuit of more effective treatments. Pharmaceutical companies, biotech firms, and research institutions heavily rely on drug discovery services to identify and develop promising drug candidates.

One of the primary drivers shaping the market dynamics is the continual advancement in technology and scientific knowledge. Breakthroughs in genomics, proteomics, high-throughput screening, and artificial intelligence have revolutionized the drug discovery process, enabling more efficient target identification, lead optimization, and preclinical testing. Consequently, companies offering cutting-edge technologies and expertise in these areas gain a competitive edge, driving the evolution of the market.

Moreover, the increasing complexity of diseases and the need for personalized medicine drive demand for specialized drug discovery services. Tailored approaches, such as precision medicine and biomarker discovery, require sophisticated platforms and expertise, fostering collaborations between pharmaceutical companies and service providers. This trend not only expands the scope of drug discovery services but also fosters innovation and differentiation among market players.

Furthermore, globalization and the outsourcing trend have reshaped the landscape of drug discovery services. Pharmaceutical companies seek to leverage cost efficiencies, access specialized expertise, and accelerate the drug development process by outsourcing various stages of drug discovery. As a result, contract research organizations (CROs) and academic research centers play a pivotal role in providing end-to-end services, ranging from target validation to IND-enabling studies. This outsourcing trend fosters a highly competitive market environment, characterized by consolidation, strategic partnerships, and geographic expansion.

However, the drug discovery services market is not without its challenges and uncertainties. Regulatory complexities, intellectual property issues, and stringent quality standards pose significant hurdles for market players. Moreover, the inherent risks associated with drug development, including high failure rates and lengthy development timelines, necessitate substantial investments in R&D and infrastructure. Market participants must navigate these challenges while remaining agile and adaptive to changing market dynamics.

In addition, the COVID-19 pandemic has exerted profound impacts on the drug discovery services market. The urgent need for therapeutics and vaccines has accelerated research and development efforts, driving demand for contract research services and innovative technologies. Virtual collaborations, remote monitoring, and digital platforms have become essential tools for conducting research amidst lockdowns and travel restrictions. While the pandemic has presented challenges, it has also catalyzed innovation and collaboration within the drug discovery ecosystem.

Looking ahead, the drug discovery services market is poised for robust growth, fueled by increasing investments in biopharmaceutical R&D, technological advancements, and the pursuit of novel therapies. Emerging trends such as gene editing, RNA therapeutics, and cell-based therapies hold immense promise for transforming drug discovery and addressing unmet medical needs. Market players must remain attuned to these trends, capitalize on emerging opportunities, and prioritize agility and innovation to thrive in an ever-evolving landscape.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What is the projected growth of the Drug Discovery Services market?

The Drug Discovery Services market is the expected increase in total market value of 106.71 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Drug Discovery Services market?

Drug Discovery Services market size was valued at approximately 24.96 billion USD in 2024. This figure will reach 106.71 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Drug Discovery Services market?

Drug Discovery Services market is expected to grow at a CAGR of 14.12% between 2025 and 2035.

How much will the Drug Discovery Services market be worth by 2035?

Drug Discovery Services market is expected to be worth of 106.71 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Drug Discovery Services market perform over the next 10 years?

Over the next 10 years the Drug Discovery Services market is expected to shift from usd billion 24.96 to 106.71 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which Region held the largest market share in the Drug Discovery Services market?

North America had the largest share in the global Drug Discovery Services market.

Market Summary

As per MRFR analysis, the Drug Discovery Services Market was estimated at 24.96 USD Billion in 2024. The Drug Discovery Services industry is projected to grow from 28.48 USD Billion in 2025 to 106.71 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 14.12 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Drug Discovery Services Market is poised for substantial growth driven by technological advancements and evolving healthcare needs.

  • The integration of Artificial Intelligence is transforming drug discovery processes, enhancing efficiency and accuracy.
  • Personalized medicine is gaining traction, leading to tailored therapeutic approaches that cater to individual patient profiles.
  • North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for drug discovery services.
  • Rising demand for biopharmaceuticals and advancements in genomics and proteomics are key drivers propelling the market forward.

Market Size & Forecast

2024 Market Size 24.96 (USD Billion)
2035 Market Size 106.71 (USD Billion)
CAGR (2025 - 2035) 14.12%
Largest Regional Market Share in 2024 North America

Major Players

<p>Thermo Fisher Scientific (US), Charles River Laboratories (US), Covance (US), WuXi AppTec (CN), Evotec (DE), Sygnature Discovery (GB), Medpace (US), PRA Health Sciences (US), BioDuro (US)</p>

Market Trends

The Drug Discovery Services Market is currently experiencing a transformative phase, characterized by a convergence of advanced technologies and innovative methodologies. This evolution is largely driven by the increasing complexity of drug development processes, which necessitates a more integrated approach to research and development. As pharmaceutical companies seek to enhance their productivity and efficiency, they are increasingly outsourcing various stages of drug discovery to specialized service providers. This trend not only allows for cost reduction but also enables access to cutting-edge technologies and expertise that may not be available in-house. Moreover, the growing emphasis on personalized medicine is reshaping the landscape of the Drug Discovery Services Market. Companies are now focusing on tailoring treatments to individual patient profiles, which requires a deeper understanding of genetic and molecular factors. This shift is prompting service providers to adopt more sophisticated analytical techniques and data management systems. As a result, the market is likely to witness a surge in demand for services that facilitate biomarker discovery, high-throughput screening, and other advanced methodologies that support the development of targeted therapies. Overall, the Drug Discovery Services Market appears poised for substantial growth, driven by technological advancements and evolving healthcare needs.

Integration of Artificial Intelligence

The incorporation of artificial intelligence in the Drug Discovery Services Market is becoming increasingly prevalent. AI technologies are being utilized to streamline various phases of drug development, from target identification to lead optimization. This integration enhances the efficiency of research processes, potentially reducing the time and resources required to bring new drugs to market.

Focus on Personalized Medicine

There is a notable shift towards personalized medicine within the Drug Discovery Services Market. This trend emphasizes the development of tailored therapies that cater to individual patient characteristics. As a result, service providers are adapting their methodologies to include advanced genomic and proteomic analyses, which facilitate the creation of more effective and targeted treatment options.

Expansion of Collaborative Partnerships

The Drug Discovery Services Market is witnessing an increase in collaborative partnerships among pharmaceutical companies, academic institutions, and service providers. These alliances are formed to leverage shared expertise and resources, fostering innovation in drug discovery. Such collaborations are likely to enhance the overall efficiency of the drug development process, leading to more rapid advancements in therapeutic solutions.

Drug Discovery Services Market Market Drivers

Rising Demand for Biologics

The Global Drug Discovery Services Market Industry experiences a notable increase in demand for biologics, driven by advancements in biotechnology and a growing understanding of complex diseases. Biologics, including monoclonal antibodies and vaccines, represent a significant portion of new drug approvals. In 2024, the market is projected to reach 25.0 USD Billion, reflecting the industry's shift towards biologics. This trend is expected to continue as more companies invest in biologics research and development, potentially leading to a market value of 106.7 USD Billion by 2035. The emphasis on biologics is likely to propel the Global Drug Discovery Services Market Industry forward, as companies seek innovative solutions to address unmet medical needs.

Growing Prevalence of Chronic Diseases

The Global Drug Discovery Services Market Industry is propelled by the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders. As these diseases continue to rise globally, there is an urgent need for effective therapeutic solutions, driving demand for drug discovery services. Pharmaceutical companies are focusing on developing targeted therapies and personalized medicine approaches to address these health challenges. The market's growth is expected to align with the rising incidence of chronic diseases, contributing to a projected market value of 106.7 USD Billion by 2035. This growing health burden underscores the importance of the Global Drug Discovery Services Market Industry in developing innovative treatments.

Regulatory Support for Drug Development

Regulatory agencies worldwide are increasingly supporting drug development processes, which positively impacts the Global Drug Discovery Services Market Industry. Initiatives aimed at expediting the approval of new drugs, such as the FDA's Breakthrough Therapy Designation, encourage innovation and reduce time to market for new therapies. This regulatory support fosters a conducive environment for drug discovery, enabling companies to bring novel treatments to patients more efficiently. As a result, the market is likely to experience substantial growth, with projections indicating a rise from 25.0 USD Billion in 2024 to 106.7 USD Billion by 2035. Such regulatory frameworks are essential for sustaining the momentum of the Global Drug Discovery Services Market Industry.

Technological Advancements in Drug Discovery

Technological innovations play a crucial role in shaping the Global Drug Discovery Services Market Industry. The integration of artificial intelligence, machine learning, and high-throughput screening technologies enhances the efficiency and accuracy of drug discovery processes. These advancements allow for faster identification of potential drug candidates, reducing time and costs associated with traditional methods. As a result, the market is poised for growth, with a projected compound annual growth rate of 14.12% from 2025 to 2035. The adoption of these technologies not only streamlines the drug discovery process but also improves the overall success rate of drug development, thereby driving the Global Drug Discovery Services Market Industry.

Increase in Research and Development Expenditure

The Global Drug Discovery Services Market Industry is significantly influenced by the rising expenditure on research and development (R&D) by pharmaceutical and biotechnology companies. As organizations prioritize innovation to stay competitive, R&D budgets are expanding, facilitating the exploration of novel therapeutic targets and drug modalities. This trend is particularly evident in emerging markets, where increased investment in healthcare infrastructure supports drug discovery initiatives. The anticipated growth in R&D spending is expected to contribute to the market's expansion, with projections indicating a rise from 25.0 USD Billion in 2024 to 106.7 USD Billion by 2035. Such investments are likely to enhance the capabilities of the Global Drug Discovery Services Market Industry.

Market Segment Insights

By Service Type: Preclinical Services (Largest) vs. Clinical Trials (Fastest-Growing)

<p>The Drug Discovery Services Market exhibits a diverse distribution in the service type segment, with 'Preclinical Services' leading in market share. This dominance is driven by the essential role these services play in the initial phases of drug development, ensuring that potential therapies are refined before entering clinical testing. Following closely are 'Clinical Trials', which are rapidly gaining traction and are considered crucial for the successful validation of drug efficacy and safety, thereby capturing attention from various stakeholders in the pharmaceutical sector. The growth trends within the Drug Discovery Services Market reflect an increased investment in biopharmaceutical R&D, fostering demand for both preclinical and clinical services. The urgency for expedited drug development processes has triggered innovations in these areas, particularly in clinical trials, which are adopting adaptive designs and technology to enhance efficiency. Factors driving growth include the rising prevalence of chronic diseases, an expanding pipeline of therapeutic candidates, and heightened collaboration between biotech firms and CROs, boosting the service market further.</p>

<p>Preclinical Services (Dominant) vs. Clinical Trials (Emerging)</p>

<p>In the Drug Discovery Services Market, 'Preclinical Services' stands as the dominant segment, providing critical early-stage testing that includes toxicology, pharmacokinetics, and formulation development. This segment is pivotal as it sets the groundwork for successful clinical development, ensuring that only the most promising candidates advance. On the other hand, 'Clinical Trials' is emerging rapidly as a vital service, characterized by its innovative methodologies and the utilization of advanced technologies such as real-time data analytics and digital health solutions. As clinical trials evolve, they adapt to the complexities of modern drug development, focusing on patient-centric approaches and accelerated timelines. This synergy between preclinical and clinical services enhances overall drug development efficiency.</p>

By Therapeutic Area: Oncology (Largest) vs. Neurology (Fastest-Growing)

<p>The Drug Discovery Services Market has diverse therapeutic areas, with oncology leading the segment share significantly. This dominance is attributed to the high incidence of cancer worldwide and ongoing innovations in cancer therapies. Oncology accounts for the largest portion of drug discovery services, influencing investment priorities among pharmaceutical companies. In contrast, neurology, while smaller, is experiencing rapid growth driven by increasing research funding and escalating demand for effective treatments for neurodegenerative diseases. The battle against diseases like Alzheimer's and Parkinson's is gaining momentum, reflecting in the segment's potential.</p>

<p>Oncology: Dominant vs. Neurology: Emerging</p>

<p>Oncology remains the dominant segment in the Drug Discovery Services Market, characterized by extensive research and a plethora of clinical trials aimed at developing targeted therapies and immunotherapies. This robust focus leads to considerable advancements in drug discovery processes tailored to specific cancer types. Neurology, in contrast, is emerging with a promise for substantial growth, spurred by technological advancements and increased investments in neuroscience research. The urgency to address unmet medical needs in conditions like epilepsy and multiple sclerosis enhances this segment's investment, leading to innovative service offerings and a broader pipeline of drug candidates.</p>

By Technology: High Throughput Screening (Largest) vs. Computational Drug Design (Fastest-Growing)

<p>The Drug Discovery Services Market presents a diverse range of technologies that cater to different stages of drug development. High Throughput Screening (HTS) currently holds the largest market share among these technologies, due to its efficiency in simultaneously testing thousands of compounds. On the other hand, Computational Drug Design is gaining traction, increasingly utilizing advanced algorithms and simulations to streamline drug development processes. Its emergence is reshaping how pharmaceuticals approach research and discovery, making it a key focus for growth. Growth trends in this segment are influenced by the demand for faster, more cost-effective drug development solutions. High Throughput Screening remains integral to large-scale screening initiatives, vital for identifying potential drug candidates rapidly. Meanwhile, the rise of Computational Drug Design is driven by technological advancements and the need for precision in drug profiling. The integration of AI and machine learning in these technologies is paving the way for more efficient discoveries and shorter timelines, solidifying their roles in the future for drug development strategies.</p>

<p>Technology: High Throughput Screening (Dominant) vs. Computational Drug Design (Emerging)</p>

<p>High Throughput Screening (HTS) has established itself as a dominant force in the Drug Discovery Services Market, due to its ability to efficiently test vast libraries of compounds within a brief timeframe. This method enhances the chances of identifying viable drug candidates, making it a cornerstone of modern pharmaceutical research. In contrast, Computational Drug Design is emerging as a critical technology, leveraging computer-based simulations to predict the efficacy and safety of potential drug molecules. With its emphasis on computational efficiency and accuracy, this segment is becoming increasingly crucial, especially as the industry embraces personalized medicine and more targeted therapies. Both technologies are vital for driving innovation and improving outcomes in drug discovery.</p>

By End User: Pharmaceutical Companies (Largest) vs. Biotechnology Firms (Fastest-Growing)

<p>In the Drug Discovery Services Market, the distribution of market share among end users reveals that pharmaceutical companies dominate the landscape due to their extensive research requirements and significant investments in drug development. They hold a major portion of the market, leveraging advanced drug discovery services to streamline their innovation processes. On the other hand, biotechnology firms are rising rapidly, capturing an increasing share of the market as they focus on cutting-edge technologies and personalized medicine solutions.</p>

<p>Pharmaceutical Companies (Dominant) vs. Biotechnology Firms (Emerging)</p>

<p>Pharmaceutical companies represent the dominant force in the Drug Discovery Services Market, characterized by their well-established infrastructure and significant research capabilities. They rely heavily on drug discovery services to enhance their R&D efforts, leading to quicker product development cycles and a stronger competitive edge. In contrast, biotechnology firms are emerging as key players, driven by innovation and specialization in biological research. They explore novel therapeutic approaches and are increasingly capitalizing on partnerships and collaborations, positioning themselves strategically to adapt to changing market demands and technological advancements.</p>

Get more detailed insights about Drug Discovery Services Market Research Report – Forecast to 2035

Regional Insights

North America : Leading Market Innovators

North America continues to lead the Drug Discovery Services market, holding a significant share of 12.48 in 2024. The region's growth is driven by advanced research facilities, high R&D investments, and a robust regulatory framework that encourages innovation. The increasing prevalence of chronic diseases and the demand for personalized medicine further fuel market expansion. Regulatory bodies are actively promoting initiatives to streamline drug development processes, enhancing the overall market landscape. The competitive landscape in North America is characterized by the presence of major players such as Thermo Fisher Scientific, Charles River Laboratories, and Covance. These companies leverage cutting-edge technologies and extensive expertise to offer comprehensive drug discovery solutions. The U.S. remains the leading country, supported by a strong network of biotech firms and academic institutions, fostering collaboration and innovation in drug development.

Europe : Emerging Research Hub

Europe's Drug Discovery Services market is projected to reach 6.99 by 2025, driven by increasing investments in biotechnology and pharmaceutical research. The region benefits from a strong regulatory framework that supports drug development, alongside initiatives aimed at enhancing collaboration between public and private sectors. The rising demand for innovative therapies and personalized medicine is also a key growth driver, as European countries focus on improving healthcare outcomes through advanced drug discovery techniques. Leading countries in Europe include Germany, the UK, and France, which host numerous biotech firms and research institutions. The competitive landscape is marked by the presence of companies like Evotec and Sygnature Discovery, which are at the forefront of drug discovery innovation. The European market is characterized by strategic partnerships and collaborations, enhancing the capabilities of local firms to compete on a global scale.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is witnessing significant growth in the Drug Discovery Services market, projected to reach 4.98 by 2025. This growth is fueled by increasing investments in healthcare infrastructure, a rising number of clinical trials, and a growing emphasis on research and development. Countries in this region are also focusing on regulatory reforms to streamline drug approval processes, which is expected to enhance market dynamics and attract foreign investments in drug discovery services. China and India are leading the charge in the Asia-Pacific market, with a growing number of biotech firms and research institutions. The competitive landscape features key players like WuXi AppTec, which is expanding its service offerings to meet the rising demand. The region's market is characterized by a blend of local and international firms, fostering a competitive environment that drives innovation and efficiency in drug discovery.

Middle East and Africa : Emerging Market Potential

The Middle East and Africa (MEA) region is gradually emerging in the Drug Discovery Services market, with a projected size of 0.51 by 2025. The growth is primarily driven by increasing healthcare investments and a rising focus on research and development initiatives. Governments in the region are implementing policies to enhance healthcare infrastructure and promote innovation in drug discovery, which is expected to attract global players and foster local capabilities. Countries like South Africa and the UAE are leading the way in establishing research facilities and partnerships with international firms. The competitive landscape is still developing, with opportunities for local companies to collaborate with global leaders in drug discovery. As the region continues to invest in healthcare, the potential for growth in drug discovery services is significant, paving the way for future advancements in the sector.

Key Players and Competitive Insights

The Drug Discovery Services Market is currently characterized by a dynamic competitive landscape, driven by the increasing demand for innovative therapeutics and the need for efficient drug development processes. Key players such as Thermo Fisher Scientific (US), Charles River Laboratories (US), and WuXi AppTec (CN) are strategically positioned to leverage their extensive capabilities in research and development, thereby enhancing their market presence. These companies focus on innovation and technological advancements, which are critical in meeting the evolving needs of pharmaceutical and biotechnology firms. Their collective strategies, including partnerships and regional expansions, contribute to a robust competitive environment that fosters collaboration and accelerates drug discovery timelines.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies like Covance (US) and Evotec (DE) is substantial, as they continue to set industry standards through their comprehensive service offerings and strategic initiatives. This competitive structure encourages smaller firms to innovate and differentiate themselves, thereby enriching the overall market dynamics.

In November 2025, Thermo Fisher Scientific (US) announced a strategic partnership with a leading biotechnology firm to co-develop next-generation gene therapies. This collaboration is expected to enhance their capabilities in gene editing and delivery systems, positioning Thermo Fisher as a frontrunner in the rapidly evolving field of genetic medicine. Such partnerships not only bolster their service portfolio but also signify a shift towards more integrated solutions in drug discovery.

In October 2025, Charles River Laboratories (US) expanded its global footprint by acquiring a prominent preclinical contract research organization in Europe. This acquisition is likely to enhance their service offerings and provide access to new markets, thereby strengthening their competitive edge. The move reflects a broader trend of consolidation within the industry, as companies seek to enhance their capabilities and streamline operations to better serve their clients.

In September 2025, WuXi AppTec (CN) launched a new platform aimed at integrating artificial intelligence (AI) into drug discovery processes. This initiative is indicative of the growing trend towards digitalization in the industry, as companies increasingly adopt AI to improve efficiency and reduce time-to-market for new drugs. The integration of AI technologies is expected to revolutionize traditional drug discovery methodologies, providing a competitive advantage to early adopters.

As of December 2025, the Drug Discovery Services Market is witnessing significant trends such as digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly important, as they enable companies to pool resources and expertise, thereby enhancing their competitive positioning. Looking ahead, it appears that competitive differentiation will increasingly hinge on innovation and technological advancements rather than price-based competition. Companies that prioritize reliability in their supply chains and invest in cutting-edge technologies are likely to emerge as leaders in this evolving landscape.

Key Companies in the Drug Discovery Services Market include

Industry Developments

November 2023 Evotec and Bayer enter into a new strategic collaboration to accelerate the discovery and development of new drugs for multiple therapeutic areas. Under the terms of the agreement, Evotec will provide Bayer with access to its integrated drug discovery platform, which includes its expertise in target identification and validation, hit-to-lead and lead optimization, and preclinical development.Thermo Fisher Scientific announces the launch of its new Ion PGM™ Dx Sequencing System, which is a next-generation sequencing (NGS) system that is designed to help pharmaceutical and biotechnology companies accelerate drug discovery and development.

The Ion PGM Dx Sequencing System is designed to provide accurate and reliable results for a wide range of NGS applications, including target identification, validation, and drug screening.Qiagen announces the launch of its new QIAseq Targeted DNA Panels, which are a family of NGS panels that are designed to help pharmaceutical and biotechnology companies target specific genes or regions of the genome for sequencing. The QIAseq Targeted DNA Panels are designed to provide high-quality and reliable data for a wide range of drug discovery applications.

October 2023 Bio-Rad Laboratories announces the launch of its new QX200 Droplet Digital PCR (ddPCR) System, which is a ddPCR system that is designed to provide pharmaceutical and biotechnology companies with a more accurate and sensitive way to detect genetic mutations associated with disease. The QX200 ddPCR System is designed to help pharmaceutical and biotechnology companies accelerate drug discovery and development by enabling them to identify and validate new drug targets and to screen for drug candidates that are effective against those targets.Parexel announces the acquisition of Pharmapace, a leading provider of clinical trial services.

The acquisition is expected to strengthen Parexel's position in the market of drug discovery services and to enable the company to offer a more comprehensive range of services to its clients.

September 2023 Several CROs announce new partnerships with pharmaceutical and biotechnology companies to provide drug discovery services. For example, Syneos Health announced a new partnership with AstraZeneca to provide drug discovery services for a range of therapeutic areas.

Future Outlook

Drug Discovery Services Market Future Outlook

<p>The Drug Discovery Services Market is projected to grow at a 14.12% CAGR from 2024 to 2035, driven by advancements in technology, increasing R&D investments, and a rising demand for personalized medicine.</p>

New opportunities lie in:

  • <p>Integration of AI-driven drug design platforms</p>
  • <p>Expansion of virtual screening services for lead optimization</p>
  • <p>Development of strategic partnerships with biotech firms for co-development projects</p>

<p>By 2035, the market is expected to be robust, reflecting substantial growth and innovation.</p>

Market Segmentation

Drug Discovery Services Market End User Outlook

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Academic Institutions
  • Contract Research Organizations
  • Government Research Institutes

Drug Discovery Services Market Technology Outlook

  • High Throughput Screening
  • Computational Drug Design
  • Biologics
  • Small Molecule Drug Discovery
  • Gene Therapy

Drug Discovery Services Market Service Type Outlook

  • Target Identification
  • Lead Optimization
  • Preclinical Services
  • Clinical Trials
  • Bioanalytical Services

Drug Discovery Services Market Therapeutic Area Outlook

  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Metabolic Disorders

Report Scope

MARKET SIZE 202424.96(USD Billion)
MARKET SIZE 202528.48(USD Billion)
MARKET SIZE 2035106.71(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)14.12% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledThermo Fisher Scientific (US), Charles River Laboratories (US), Covance (US), WuXi AppTec (CN), Evotec (DE), Sygnature Discovery (GB), Medpace (US), PRA Health Sciences (US), BioDuro (US)
Segments CoveredService Type, Therapeutic Area, Technology, End User
Key Market OpportunitiesIntegration of artificial intelligence in Drug Discovery Services Market enhances efficiency and accelerates drug development timelines.
Key Market DynamicsRising demand for innovative therapies drives competition and technological advancements in the Drug Discovery Services Market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the projected growth of the Drug Discovery Services market?

The Drug Discovery Services market is the expected increase in total market value of 106.71 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Drug Discovery Services market?

Drug Discovery Services market size was valued at approximately 24.96 billion USD in 2024. This figure will reach 106.71 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Drug Discovery Services market?

Drug Discovery Services market is expected to grow at a CAGR of 14.12% between 2025 and 2035.

How much will the Drug Discovery Services market be worth by 2035?

Drug Discovery Services market is expected to be worth of 106.71 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Drug Discovery Services market perform over the next 10 years?

Over the next 10 years the Drug Discovery Services market is expected to shift from usd billion 24.96 to 106.71 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which Region held the largest market share in the Drug Discovery Services market?

North America had the largest share in the global Drug Discovery Services market.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | 2.2 RESEARCH METHODOLOGY
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | 3.2 MARKET FACTOR ANALYSIS
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Service Type (USD Billion)
    2. | 4.2 Healthcare, BY Therapeutic Area (USD Billion)
    3. | 4.3 Healthcare, BY Technology (USD Billion)
    4. | 4.4 Healthcare, BY End User (USD Billion)
    5. | 4.5 Healthcare, BY Region (USD Billion)
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | 5.2 Company Profiles
    3. | 5.3 Appendix

Drug Discovery Services Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓